Cargando…

Utilization of real‐world data in assessing treatment effectiveness for diffuse large B‐cell lymphoma

Direct comparisons of the effectiveness of the numerous novel therapies in the diffuse large B‐cell lymphoma (DLBCL) treatment landscape in a range of head‐to‐head randomized phase 3 trials would be time‐consuming and costly. Comparative effectiveness studies using real‐world data (RWD) represent a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nowakowski, Grzegorz, Maurer, Matthew J., Cerhan, James R., Dey, Debarshi, Sehn, Laurie H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Critical Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092365/ https://www.ncbi.nlm.nih.gov/pubmed/36251361 http://dx.doi.org/10.1002/ajh.26767

Ejemplares similares

RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma
por: Zinzani, Pier Luigi, et al.
Publicado: (2021)

Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma
por: Desai, Sanjal H., et al.
Publicado: (2022)

Primary mediastinal large B‐cell lymphoma
por: Villa, Diego, et al.
Publicado: (2020)

Diffuse large B-cell lymphoma: new targets and novel therapies
por: Cheson, Bruce D., et al.
Publicado: (2021)

P1152: DEPTH OF METABOLIC RESPONSE AT INTERIM PET AND SURVIVAL OUTCOMES AMONG PATIENTS WITH PRIMARY REFRACTORY OR EARLY RELAPSING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Bock, Allison, et al.
Publicado: (2023)

Real‐world data for lenalidomide maintenance in responding patients of diffuse large B‐cell lymphoma
por: Wang, Xiaoyan, et al.
Publicado: (2023)

Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma
por: Wang, Yucai, et al.
Publicado: (2019)

Real-world outcomes of diffuse large B-cell lymphoma in the biosimilar era
por: Nair, Reena, et al.
Publicado: (2023)

Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression
por: Tracy, Sean I., et al.
Publicado: (2018)

Clinical Treatment Guidelines for Tafasitamab plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Nedved, Adrienne, et al.
Publicado: (2023)

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Sehn, Laurie H., et al.
Publicado: (2020)

Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy
por: Clausen, Michael R, et al.
Publicado: (2019)

PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts
por: Desai, Sanjal H., et al.
Publicado: (2022)

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2021)

Whole-exome analysis reveals novel somatic genomic alterations associated with cell of origin in diffuse large B-cell lymphoma
por: Manso, B A, et al.
Publicado: (2017)

Polymorphisms in DNA Repair and One-Carbon Metabolism Genes and Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma
por: Wang, Sophia S, et al.
Publicado: (2008)

Real-World Data Analysis of Survival Outcomes and Central Nervous System Relapses in Testicular Diffuse Large B Cell Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2023)

Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA
por: Herrera, Alex F., et al.
Publicado: (2022)

P1186: A LARGE FRENCH REAL WORLD MULTICENTRIC PROSPECTIVE COHORT OF PATIENTS WITH LYMPHOMA (REALYSA STUDY): DESCRIPTION OF THE DIFFUSE LARGE B CELL LYMPHOMA PATIENTS IN REAL WORLD IN FRANCE
por: Ghesquieres, H., et al.
Publicado: (2022)

Outcomes of diffuse large B-cell lymphoma in elderly patients—real-world experience from a middle-income country setting
por: Sarker, Chandrayee, et al.
Publicado: (2021)

A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma
por: Liu, Peng, et al.
Publicado: (2019)

Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study
por: Bolen, Christopher R., et al.
Publicado: (2019)

Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma
por: Nowakowski, Grzegorz S., et al.
Publicado: (2019)

Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey
por: Dal, Mehmet Sinan, et al.
Publicado: (2022)

Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma
por: Novak, A J, et al.
Publicado: (2015)

Outcomes in refractory diffuse large B‐cell lymphoma: results from a multicenter real‐world study in China
por: Wang, Shuo, et al.
Publicado: (2021)

Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy
por: Argnani, Lisa, et al.
Publicado: (2022)

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma
por: Bartlett, Nancy L., et al.
Publicado: (2023)

A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA
por: Sehn, Laurie H., et al.
Publicado: (2020)

Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis
por: Khor, Sara, et al.
Publicado: (2014)

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
por: Bachy, Emmanuel, et al.
Publicado: (2022)

PB2145: REAL-WORLD THERAPY LINES IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) – A POPULATION-BASED ANALYSIS
por: Duell, J., et al.
Publicado: (2022)

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma
por: Nowakowski, Grzegorz S., et al.
Publicado: (2023)

P1227: POLATUZUMAB VEDOTIN, RITUXIMAB, AND BENDAMUSTINE COMBINATION IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-WORLD DATA FROM TURKEY
por: Dal, M. S., et al.
Publicado: (2022)

Human Leukocyte Antigen Class I and II Alleles and Overall Survival in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
por: Lu, Yani, et al.
Publicado: (2011)

Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma
por: Nowakowski, Grzegorz S., et al.
Publicado: (2023)

Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study
por: Kostakoglu, Lale, et al.
Publicado: (2021)

Reduced Hospitalizations and Amputations in Patients with Diabetic Foot Ulcers Treated with Cyclical Pressurized Topical Wound Oxygen Therapy: Real-World Outcomes
por: Yellin, Jessica Izhakoff, et al.
Publicado: (2022)

Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone
por: Horvat, Matej, et al.
Publicado: (2018)

High pretreatment plasma D-dimer levels predict poor survival in patients with diffuse large B-cell lymphoma in the real world
por: Huang, Haobo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8ukufrueblvccn0vd4hbpb897e